Obermatt
See Similar Stocks →

Virbac

PAR:VIRP · FR0000031577
PharmaceuticalsSmall

360

58
EV / EBIT67
Price / Owner Earnings37
Owner Earnings Yield65
Dividend Yield49
Price/Sales90
EV / Gross Profit85
Price/Book70
Return on Capital75
Cash Return on Capital50
Return on Equity60
EBIT Margin45
Gross Profitability72
Cash Conversion51
Accruals30
Owner Earnings Margin33
Sales growth46
Profit Growth57
Long-Term EPS Growth43
Owner Earnings Growth59
Reinvestment89
Price momentum44
Debt load49
Refinancing84
Debt Payback29
Liquidity70
Analyst ratings64
Opinion Changes14
Price Target Upside26
Market mood35
Value Creation16/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Virbac generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryFrance
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeENXTPA
Founded1973
Employees3,534
Websitecorporate.virbac.com
ISINFR0000031577
Last UpdateApr 2, 2026
Indices
CAC All (France)SBF 120 (France)Sound Pay Practices (Europe)
Themes
LivestockDermatologyPet CarePet Food and SuppliesVaccinesPharmaceutical

Description

Virbac SA manufactures and sells a range of products and services for companion animals and farm animals. Business Segments The company is structured into geographical segments, which include France, Europe (excluding France), Latin America, North…

Analysis

Middle-of-the-road

Virbac SA sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is expensive. The owner-earnings multiple stands at 26.8×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 10% a year, against analyst forecasts of 7%. The price, in other words, assumes less than the experts do.

Growth is moderate; the safety picture is adequate. The company scores 16/20 on our value-creation score: strong value creator.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
94
2023202420252026

All-time high

98

Feb 2024

All-time low

70

Sep 2025

Average rank

89

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
90
59
63
69
Price/Earnings
50
54
33
32
Price/Book
70
45
43
43
Dividend Yield
49
33
45
43
Value (overall)
85
70
49
61

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Virbac with its peers
Vetoquinol
PAR:VETO
76
CountryFrance
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
GSK
LSE:GSK
72
CountryUK
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Recordati
MIL:REC
54
CountryItaly
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Krka
LJU:KRKG
63
CountrySlovenia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Avadel Pharmaceuticals
NMQ:AVDL
70
CountryIreland
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Almirall
MCE:ALM
74
CountrySpain
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →